Vertex has recorded some 25,000 prescriptions for Journavx since its January approval and is in the process of getting big ...

Vertex Pharmaceuticals sees brighter prospects despite Q1 misses, with promising launches, pipeline progress, and upgraded ...

Vertex Pharmaceuticals stock was falling sharply Tuesday after the biotech company reported first-quarter earnings that ...

Q1 2025 Management View CEO Reshma Kewalramani highlighted $2.77 billion in revenue for Q1 2025, reflecting 3% growth ...

Vertex's diversification efforts are most visible in the progress of its pain management portfolio. Read why I rate VRTX ...

For Vertex Pharmaceuticals, the first quarter of 2025 brought good news and bad news. | Despite positive early signs for its ...

The new campaign stars former NFL quarterback Alex Smith, whose leg injury during a 2018 game led to a case of ...

Agents that target NaV1.8, a voltage-gated sodium channel, are showing promise. The FDA approved one of them, Journavx ...

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reports Q1 earnings with $4.32 EPS and $2.85B revenue. Stock up 25.48% in past year, ...

Vertex gained approval for two new products, its novel non-opioid pain medicine Journavx (suzetrigine) and its fifth CF medicine, Alyftrek, in the last few months. Vertex and partner CRISPR ...

Vertex Pharmaceuticals Inc (VRTX) reports a 3% revenue increase, driven by US growth and new product launches, despite ...